Pharmaceutical Development of Green Innovation Group, Pharmacy, Silpakorn University, Nakhon Pathom, 73000, Thailand.
Nanomedicine (Lond). 2013 Nov;8(11):1865-73. doi: 10.2217/nnm.13.155.
RNAi is a promising potential therapeutic approach for many diseases. A major barrier to its clinical translation is the lack of efficient delivery systems for siRNA. Among nonviral vectors, nonionic surfactant vesicles (niosomes) have shown a great deal of promise in terms of their efficacy and toxicity profiles. Nonionic surfactants have been shown to be a superior alternative to phospholipids in several studies. There is a large selection of surfactants with various properties that have been incorporated into niosomes. Therefore, there is great potential for innovation in terms of nisome composition. This article summarizes recent advancements in niosome technology for the delivery of siRNA.
RNAi 是一种有前途的潜在治疗方法，可用于许多疾病。其临床转化的主要障碍是缺乏有效的 siRNA 递送系统。在非病毒载体中，非离子表面活性剂囊泡（niosomes）在功效和毒性特征方面显示出巨大的潜力。在几项研究中，非离子表面活性剂已被证明是磷脂的优越替代品。有多种具有不同性质的表面活性剂已被纳入 niosomes。因此，在 niosome 组成方面有很大的创新潜力。本文总结了最近在用于递送 siRNA 的 niosome 技术方面的进展。
